key: cord-1022201-yi9n0d0a authors: Soni, Shringika; Namdeo Pudake, Ramesh; Jain, Utkarsh; Chauhan, Nidhi title: A systematic review on SARS‐CoV‐2‐associated fungal coinfections date: 2021-10-05 journal: J Med Virol DOI: 10.1002/jmv.27358 sha: b3c4b1893201a875cdc74595c33353bda1d6ed42 doc_id: 1022201 cord_uid: yi9n0d0a A severe pandemic of Coronavirus Disease (COVID‐19) has been sweeping the globe since 2019, and this time, it did not stop, with frequent mutations transforming into virulent strains, for instance, B.1.1.7, B.1.351, and B.1.427. In recent months, a fungal infection, mucormycosis has emerged with more fatal responses and significantly increased mortality rate. To measure the severity and potential alternative approaches against black fungus coinfection in COVID‐19 patients, PubMed, Google Scholar, World Health Organization (WHO) newsletters, and other online resources, based on the cases reported and retrospective observational analysis were searched from the years 2015–2021. The studies reporting mucormycosis with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) coinfection and/or demonstrating potential risk factors, such as a history of diabetes mellitus or suppressed immune system were included, and reports published in non‐English language were excluded. More than 20 case reports and observational studies on black fungus coinfection in COVID‐19 patients were eligible for inclusion. The results indicated that diabetes mellitus, hyperglycemic, and immunocompromised COVID‐19 patients with mucormycosis were at a higher risk. We found that it was prudent to assess the potential risk factors and severity of invasive mycosis via standardized diagnostic and clinical settings. Large‐scale studies need to be conducted to identify early biomarkers and optimization of diagnostic methods has to be established per population and geographical variation. This will not only help clinicians around the world to detect the coinfection in time but also will prepare them for future outbreaks of other potential pandemics. Mucormycosis (zygomycosis) is an acute and fatal, but rare fungal infection caused by a category of molds called mucormycetes, under subphylum Mucormycotina and order Mucorales. 8, 9 A total of 11 genera and~27 species have been reported under order Mucorales, among them, Rhizopus is the predominant genera followed by Mucor and Lichtheimia. 10 Mucorales fungi are commonly found in hematological malignancies and stem cells or solid organ transplantation. 11, 12 Recently, an epidemical emergency of a black fungus with an aggressive and contiguous spread in COVID-19 patients has been reported. Patients who had a history of diabetes mellitus, immunocompromised conditions, and recently underwent bone marrow transplants were vulnerable to this coinfection. The COVID-19 condition also provides an ideal environment, such as hypoxia, high glucose (diabetes or steroid-induced hyperglycemia), increased ferritin, low phagocytic activity of white blood cells (WBCs) to facilitate germination of fungal spores, metabolic acidosis, and diabetes ketoacidosis induced acidic medium. 13 Additionally, the altered response of T-helper cells, higher proinflammatory and anti-inflammatory cytokines, and cytokine release syndrome that induce lung pathology in COVID-19 patients also promote pulmonary microbial proliferation. 14, 15 Although, several case reports and observational studies on mucormycosis in COVID-19 patients have been reported, information on frequency, incidence, and susceptibility profiles of secondary infections remain scarce, even after the availability of detailed COVID-19 data. 16 It is also challenging for clinicians to differentiate between the SARS-CoV-2 virus and possible superadded fungus infection. Progressive coinfection of mucormycosis in COVID-19 patients has caused new challenges for researchers, and clinicians, which includes identification and diagnosis of the pathogens. Initially, in 2021, India became a major hotspot for black fungus coinfection with SARS-CoV-2, and widespread use of steroids in COVID-19 treatment increased the risk of mucormycosis. Additionally, India is reported to have~80 times higher incidence rate of mucormycosis in comparison to developed countries, 17 therefore, the second invasion of SARS-CoV-2 had dramatic effects on human health and the economy. Health-care professionals were facing problems with timely diagnosis and appropriate treatment while considering underlying comorbid conditions of the patients. Moreover, the shortage of medical resources such as beds and medications for mucormycosis-SARS-CoV-2 coinfection is not only affecting health-care systems, it also requires collecting measurable evidence to prepare the medical world for future outbursts. With all this in mind, the present systematic review focused on the detailed summary of mucormycosis cases reported in COVID-19 patients, with a major focus on current limitations and challenges in diagnostics and pharmaceutical interventions. To design a systematic search strategy to investigate fungal infection in COVID-19 positive patients; PubMed (https://pubmed.ncbi.nlm. nih.gov/), Google Scholar (https://scholar.google.com/), and other online web sources were searched from the last 5 years and analyzed using terminologies such as "COVID-19," "SARS-CoV-2," "Fungal infection," "Mucormycete," "Black Fungus," "mucormycosis," "Immune signaling," "Immunotherapy," "Diagnosis," and "Treatment." The criteria for the selection of observational or case reports as primary studies was their surveillance of (i) COVID-19 patients of any age and gender with a fungal infection, (ii) In-house hospitalized and discharged COVID-19 patients with immunocompromised diseases and comorbid conditions, (iii) clinical studies or literature reviews on prescribed treatment and diagnostic methods for COVID-19 coinfection. We excluded studies that reported clinical efficacy and mortality rate with no targeted outcomes. Unpublished data, thesis work, press releases, and literature in other languages (except English) were also excluded. Furthermore, to provide relevant information, articles focusing on potential risks of SARS-CoV-2 and "black fungus" in the Indian scenario and optimal risk were profoundly studied. The preliminary screening of the literature search assimilated 237 potential results, among them 146 articles fulfilled the inclusion criteria, containing 135 published articles, and 11 online web sources. After abstract and methodology screening, 81 articles and documents were shortlisted, and 65 were excluded, due to 59 articles' specified exclusion criteria and 6 articles being in a language other than English. The flowchart of articles' selection and exclusion is illustrated in were initially reported to associate with subsequent bacterial infections, especially Streptococcus pneumonia (S. pneumonia). 18, 19 Despite the demonstration of severe coinfection existence in respiratory diseases, the current situation of COVID-19 with fungal coinfections is understudied. Fungal infections were not very common, yet were serious complications in SARS-CoV-2 induced pneumonia in critically ill or hospitalized patients. In our literature search, very limited articles reported on fungal coinfection in COVID-19 patients, and very few provided details of the associated mechanism of action of pathogens. Even so, we analyzed these studies and focused on potential outcomes to control the epidemic. patients. 23 Patients majorly reported respiratory distress and prolonged fever followed by lymphopenia, leukopenia, and leukocytosis. In summary, overlapped symptoms and masked laboratory tests in the above studies are indicating the possibility of certain interactions between fungi and SARS-CoV-2, which is yet to be explored at the molecular level. However, potential association and risk factors in SARS-CoV-2 and black fungus coinfection are illustrated in Figure 2 . Major fungi with SARS-CoV-2 coinfection belong to the category of Aspergillus, Candida, and Klebsiella, 24 which were reported as common secondary infections. Unlike last year, "black fungus" coinfection was a major cause of death in COVID-19 patients, especially in India. 25, 26 Looking back on the SARS epidemic in the year 2003, China-based studies stated that 14.8%-27% of SARS patients were coinfected with fungus and the mortality rate was exaggerated by 25%-73.7%, which was higher than that of severely ill patients (up to 21.9%-33%). 27, 28 In a similar direction, studies demonstrated 5.0% 29 and 5.8% 30 COVID-19 positive critically ill patients with fungal coinfection. However, the low infection rate did not alarm the health authorities at the time. Moreover, additional shared risk factors were studied in COVID-19 patients to further explore the potential association between the pathogens. For this, not limited to the severity of coinfections in the intensive care unit (ICU) hospitalized COVID-19 patients, the following characteristics were also recognized 14,31,32 : (1) Profound immunosuppression due to disease severity or genetic inheritance. (2) Cytokine storm during hematopoietic transplantation. (3) Heavily mechanically ventilated during long-term hospitalization. F I G U R E 1 Preferred reporting flow chart for including and studying studies and case reports for systematic review (4) Corticosteroid medications during diabetes mellitus. The differential symptoms of SARS-CoV-2 and fungal coinfection are yet to be discovered, and the balance between underlying disease and SARS-CoV-2 infection as a potential risk factor for fungal infection has not been identified to date. 31 Therefore, surveys at a large scale and sufficient descriptions of symptoms during patients' registration should be made mandatory. Gradual increment in mucormycosis in COVID-19 patients across the globe is causing an additional challenge in the identification and diagnosis of fungal infection on time. In this direction, the French High Council for Public Health has recommended systematic screening of mucormycosis coinfection in COVID-19 patients. 31 The symptoms of mucormycosis are not specific, however, ophthalmoplegia, headache, watery eyes, blackish appearance on the skin or mucosa, and fever are reported in mucormycosis and SARS-CoV-2 coinfection. [33] [34] [35] Fungal coinfection in COVID-19 patients is generally suspected on the basis of direct microscopical imaging or plus fluorescent brighteners in biological samples such as sputum, skin lesions, and Bronchoalveolar Lavage Fluid (BALF), unlike COVID-19 detection. [36] [37] [38] Radiographic features, such as pansinusitis or ethmoid sinusitis, nodular lesions, and reverse halo signs are also helpful in invasive mucormycosis detection in COVID-19 patients. 36 However, in terms of laboratory tests, mucormycosis shows negative results in galactomannan index and beta 1, 3-D-glucan (BDG) assays, unlike Aspergillus, whereas R. oryzae is known to have betaglucan synthase to synthesize beta-glucan. 39 Hence, this assay needs to be modified and revised as per biomarkers associated with SARS-CoV-2 coinfection, as it was negative in one case report. 40 Additionally, antigen-antibody-based serological tests, such as Enzyme-Linked Immunosorbent Assay (ELISA), immunoblots, and immunodiffusion tests can be also used to detect mucormycosis coinfection in COVID-19 patients. 37, 41 In this direction, a monoclonal antibody (namely, 2DA6) that recognizes α−1,6-linked mannose, can be used, which is conserved in both Zygomycota and Ascomycota. 37 Therefore, the proposed immunodiagnostic method cannot be considered to differentiate specific black fungus in COVID-19 patients. Polymerase Chain Reaction (PCR), Restriction Fragment Length Polymorphism (RFLP), real-time PCR, and sequencing to identify mucormycosis. 37, 42 These methods mainly target Internal Transcribed Spacer (ITS) or 18 S rRNA gene of the pathogens, however, ITS is highly specific for Mucorales detection, unlikely to detect other fungi which come under Mucormycetes. 41 Additionally, these in-house F I G U R E 2 Representation of the potential association between SARS-CoV-2 and mucormycosis assays are not widely studied, and clinical evaluation is still missing. A life-threatening condition of mucormycosis is an invasive and progressive fungal infection with a 50% mortality rate. 48 However, a majority of 70% of cases from all mucormycosis is caused by R. arrhizus, which is recently reported to be linked with SARS-CoV-2 coinfection. 49, 50 The main risk factor of mucormycosis is reported higher in COVID-19 patients with comorbid conditions of rhinoorbital-cerebral, uncontrolled diabetes mellitus with ketoacidosis, gastric and pulmonary diseases, hematological malignancy, and longterm corticosteroid usage. 40, 51, 52 These factors confirmed the potential synergistic effect between black fungus and SARS-CoV-2 pathogens. The major overlapping potential mechanisms involved in the proposed coinfection might be as follows: (1) Fungal coinfection in COVID-19 was reported to increase the degree of systemic inflammation, hence, inflation in disease severity, and mortality rate were observed in the patients. To evaluate this concept, Tan et al. reported an increased level of proinflammatory cytokines, especially Interleukin-6 (IL-6), which was associated with severe lung injury in coinfected patients. 53 Additionally, lymphocytes (such as B-cells, T-cells, and natural killer cells [NK] ) were reported to be altered and affected host immune functions to provide a suitable environment for coinfection. 54, 55 (2) Patients with diabetes mellitus also have dysfunctional immune system components due to severe inflammatory states. Low level of C4 complement protein along with altered functionality of neutrophils, truncated response to cytokines and reduced IL-10 production was reported as the result of increased glycosylation in diabetic patients. 56 treatment. A multicentric retrospective study in India also showed a major risk factor in diabetes mellitus (75%) in COVID-19 and mucormycosis coinfection in comparison to chronic kidney disease (12.5%), chronic liver disease (6.25%), pulmonary tuberculosis (TB) (6.25%), and patients on immunosuppressive agents (6.25%). 70 Glucocorticoids are reported to cause immunosuppressive effects via transcriptional upregulation or repression of specific genes, especially nuclear factor κB (NF-κB). 71, 72 It also affects T-lymphocyte Not restricted to pulmonary, nasal, or oral mucormycosis, conjunctival mucosa (rhino-orbito-cerebral) derived fungal infection is another coinfection in COVID-19 patients. COVID-19 has a propensity to induce extensive pulmonary disease along with alveolointerstitial pathology, which is itself a risk factor for invasive fungal infection in sinuses and lungs. 74 Major rhino-orbito-cerebral mucormycosis-associated cases have been found in COVID-19 patients with a history of ketoacidosis diabetes mellitus with initial symptoms of acute sinusitis, nasal discharge, headache, and fever, which later spread to the orbital system. In this systematic review, we studied~30 case reports and observational studies in which patients showed mucormycosis in COVID-19 patients, among them, 70% of patients died due to the lack of timely diagnosis. These studies also demonstrated that COVID-19-associated mucormycosis is majorly linked to immunity deterioration, extensive use of steroids, and broad-spectrum antibiotics, used during treatment of critically ill SARS-CoV-2 patients. The curve of multipathogen coinfection in COVID-19 patients also increased in the initial month of the year 2021 and has compromised reliable clinical diagnosis and treatment. Therefore, clinicians should be aware of the possibility of secondary infections, especially in patients with pre-existing risk factors, such as diabetes mellitus, neutropenia, and immunocompromised conditions (HIV, tumor, or organ transplant). In this study, we analyzed case reports and observational studies that have reported pulmonary, orbital, cerebral, and gastrointestinal mucormycosis involvement in SARS-CoV-2 coinfection and concluded that~80% of cases had a history of hyperglycemic conditions. However, post-COVID mucormycosis showed a lower risk of fungal coinfection-associated mortality. We consider that it is important to identify the potential association among biomarkers and pathways of relevant coinfection of the current scenario. As PCR is a major diagnostic method for SARS-CoV-2 detection and histopathology is mainly considered for mucormycosis, radio diagnostic methods are the most reliable technique for coinfection detection. What's the risk of dying from a fast-spreading COVID-19 variant? Why is India having a covid-19 surge? Fungal co-infection in COVID-19 patients: should we be concerned? Immunopathology of SARS-CoV-2 infection: immune cells and mediators, prognostic factors, and immune-therapeutic implications Optimizing testing regimes for the detection of COVID-19 in children and older adults Profile of co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: implication on antimicrobial resistance Community-acquired viral respiratory infections amongst hospitalized inpatients during a COVID-19 outbreak in Singapore: coinfection and clinical outcomes Taxonomy of fungi causing mucormycosis and entomophthoramycosis (Zygomycosis) and nomenclature of the disease: molecular mycologic perspectives Invasive mold infections: virulence and pathogenesis of mucorales Mucormycosis: an opportunistic pathogen during COVID-19 Invasive mucormycosis in children with malignancies: report from the infection working group of the hellenic society of pediatric hematology-oncology Mucormycosis in lung transplant recipients: a systematic review of the literature and a case series Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India Co-infections in people with COVID-19: a systematic review and meta-analysis Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: a systematic review Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09 COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan COVID-19: a promising cure for the global panic Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: species identification and antifungal susceptibility pattern Co-infection with respiratory pathogens among COVID-2019 cases Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China Misfortune never comes alone -the new "Black Fungus" accompanying COVID-19 wave Hospital acquired pneumonia occurring after acute stage of the serious SARS and its treating strategies Clinical analysis of 146 patients with critical severe acute respiratory syndrome in Beijing areas Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study Invasive fungal diseases during COVID-19: we should be prepared Fungal infections in COVID-19-positive patients: a lack of optimal treatment options Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum Covid-19: India sees record deaths as "black fungus" spreads fear The unseen "fungal infections"-an extra thrust aggravating COVID second wave in India Mucormycosis in a 40-year-old woman with diabetic ketoacidosis Recent advances in the molecular diagnosis of mucormycosis New and developing diagnostic platforms for COVID-19: a systematic review A potential explanation of a positive serum β-Glucan assay in mucormycosis Autopsy proven pulmonary mucormycosis due to rhizopus microsporus in a critically Ill COVID-19 patient with underlying hematological malignancy Challenges in the diagnosis and treatment of mucormycosis Laboratory diagnosis of mucormycosis: current status and future perspectives MS for the diagnosis of infectious diseases COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature Influenza and bacterial coinfection in adults with community-acquired pneumonia admitted to conventional wards: risk factors, clinical features, and outcomes ICU Admissions for sepsis or pneumonia in Australia and New Zealand in 2017 Mucormycosis of the head and neck: report of five cases with different presentations Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study Systemic and gastrohepatic mucormycosis in dogs Rare and fatal gastrointestinal mucormycosis (zygomycosis) in a COVID-19 patient: a case report A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19 Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study Combination of lymphocyte number and function in evaluating host immunity One case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a low CD4+ T-cell count Coincidence of uncontrolled diabetes mellitus and COVID-19 Is a serious threat to Mucormycosis: a systematic review Lactoferrin, a potential ironchelator as an adjunct treatment for mucormycosis-a comprehensive review Diabetes, infection risk and COVID-19 Are people with uncontrolled diabetes mellitus at high risk of reinfections with COVID-19? Prim Care Diabetes Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities? Targeting iron acquisition blocks infection with the fungal pathogens Aspergillus fumigatus and Fusarium oxysporum Host-pathogen molecular factors contribute to the pathogenesis of rhizopus spp. in diabetes mellitus When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators What can cellular redox, iron, and reactive oxygen species suggest about the mechanisms and potential therapy of COVID-19? Mucormycosis-a serious threat in the COVID-19 pandemic? A Fatal case of rhizopus azygosporus pneumonia following COVID-19 A case report of COVID-19 associated pulmonary mucormycosis. Arch Clin Cases Post-COVID pulmonary mucormycosisa case report Clinical characteristics and outcomes of 16 cases with COVID19 and mucormycosis: experience from a tertiary care center in India and review of literature. Res Sq More than suppression: glucocorticoid action on monocytes and macrophages Fighting the fire: mechanisms of inflammatory gene regulation by the glucocorticoid receptor Immune regulation by glucocorticoids Rhino-orbital mucormycosis associated with COVID-19 Acute invasive rhinoorbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report Sinoorbital mucormycosis in a COVID-19 patient: a case report Rhinocerebral mucormycosis and COVID-19 pneumonia Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19 A systematic review on SARS-CoV-2-associated fungal coinfections The authors declare that there are no conflict of interests. Data sharing is not applicable to this article as no new data were created or analyzed in this study. http://orcid.org/0000-0002-5620-9722Utkarsh Jain http://orcid.org/0000-0003-3901-0153Nidhi Chauhan http://orcid.org/0000-0001-9512-1144